Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

NCT06455748 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Amyloid Light-chain Amyloidosis

Interventions

DRUG: Daratumumab/daratumumab and hyaluronidase-fihj
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Yongyong MA